Velcade sNDA seeks full approval, second-line use
This article was originally published in Pharmaceutical Approvals Monthly
You may also be interested in...
Millennium Velcade Has 50%-60% Of Third-Line Multiple Myeloma Market
Millennium’s Velcade captured 50% to 60% of the third-line multiple myeloma market in the second quarter, the firm reported July 22.
New EU Approvals
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add two new products, including Ryzneuta, Evive Biotechnology's treatment for chemotherapy-induced neutropenia.
Pair Of Deaths Linked To Recalled Vyaire Medical Respiratory Devices
The US FDA has labelled a recall of more than 6 million Airlife respiratory support devices class I. The recall covers devices manufactured in 2017 or earlier that can fail to provide adequate ventilation.